KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.

Clara I Saldarriaga, Faiez Zannad, Ciaran J McMullan, Aiwen Xing, Davis Gates, Kevin J Anstrom, Marc P Bonaca, Stefano Corda, Justin A Ezekowitz, Carolyn S P Lam, Eldrin F Lewis, JoAnn Lindenfeld, Robert J Mentz, Christopher O'Connor, Mahesh Patel, Piotr Ponikowski, Yogesh N V Reddy, Giuseppe M C Rosano, Michele Senni, James Udelson, Adriaan A Voors, Javed Butler

Eur J Heart Fail 27(8) 1426-1435

PMID39956649
PMCIDPMC12482839
DOI10.1002/ejhf.3598
发表日期2025-02-16
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other。
摘要

摘要

AIMS: To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND RESULTS: Baseline characteristics were evaluated in 6105 patients randomized to vericiguat or placebo. The mean age of the participants was 67 ± 11 years, 23.6% were women, 64.4% were White, and 10.7% were self-identified Black. Overall, 29.1% of participants were enrolled in Latin and South America, 27.8% and 18.5% in Eastern and Western Europe, 14.0% in Asia-Pacific and 10.6% in North America. The mean left ventricular ejection fraction was 30 ± 7% and 79% had New York Heart Association class II symptoms. Mean estimated glomerular filtration rate was 70.9 ± 24.0 ml/min/1.73 m2. Median N-terminal pro-B-type natriuretic peptide level was 1476 (970-2495) pg/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin-angiotensin system modulation (including 56.0% on an angiotensin receptor-neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium-glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy. CONCLUSION: The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 History of hospitalization for heart failure.
非 KM Figure
Figure 2Figure 2 Proportion of guideline‐directed drug and device therapy across contemporary heart failure with reduced ejection fraction trials. ARNI, angiotensin receptor–neprilysin inhibitor; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter‐defibrillator; MRA, mineralocorticoid receptor antagonist; RASi, renin–angiotensin system inhibitor; SGLT2i, sodium–glucose cotransporter 2 inhibitor.
非 KM Figure